Trial · NCT02493868
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Phase: DE Participants | STARTED | Intranasal Esketamine + Oral AD | 437 | |
| Induction Phase: DE Participants | STARTED | Oral AD + Intranasal Placebo | 0 | |
| Induction Phase: DE Participants | COMPLETED | Intranasal Esketamine + Oral AD | 273 | |
| Induction Phase: DE Participants | COMPLETED | Oral AD + Intranasal Placebo | 0 | |
| Induction Phase: DE Participants | NOT COMPLETED | Intranasal Esketamine + Oral AD | 164 | |
| Induction Phase: DE Participants | NOT COMPLETED | Oral AD + Intranasal Placebo | 0 | |
| Optimization Phase: DE+TE Participants | STARTED | Intranasal Esketamine + Oral AD | 455 | |
| Optimization Phase: DE+TE Participants | STARTED | Oral AD + Intranasal Placebo | 86 | |
| Optimization Phase: DE+TE Participants | COMPLETED | Intranasal Esketamine + Oral AD | 297 | |
| Optimization Phase: DE+TE Participants | COMPLETED | Oral AD + Intranasal Placebo | 54 | |
| Optimization Phase: DE+TE Participants | NOT COMPLETED | Intranasal Esketamine + Oral AD | 158 | |
| Optimization Phase: DE+TE Participants | NOT COMPLETED | Oral AD + Intranasal Placebo | 32 | |
| Maintenance Phase: DE+TE Participants | STARTED | Intranasal Esketamine + Oral AD | 152 | |
| Maintenance Phase: DE+TE Participants | STARTED | Oral AD + Intranasal Placebo | 199 | |
| Maintenance Phase: DE+TE Participants | Stable Remitters | Intranasal Esketamine + Oral AD | 90 | |
| Maintenance Phase: DE+TE Participants | Stable Remitters | Oral AD + Intranasal Placebo | 86 | |
| Maintenance Phase: DE+TE Participants | Stable Responders | Intranasal Esketamine + Oral AD | 62 | |
| Maintenance Phase: DE+TE Participants | Stable Responders | Oral AD + Intranasal Placebo | 59 | |
| Maintenance Phase: DE+TE Participants | COMPLETED | Intranasal Esketamine + Oral AD | 139 | |
| Maintenance Phase: DE+TE Participants | COMPLETED | Oral AD + Intranasal Placebo | 177 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02493868/flow